Recapture of hepatic apolipoprotein B mRNA editing may be a promising strategy to relieve nephrotic dyslipidemia

Medical Hypotheses

Volumn 75, Issue 6, 2010, Pages 561-563

  Hu, Peng ^a   Lu, Ling ^a   Hu, Bo ^a   Qin, Yuan Han ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; APOLIPOPROTEIN B; MESSENGER RNA;

ARTICLE; DYSLIPIDEMIA; GENE EXPRESSION; GENE THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DISEASE; LIPID METABOLISM; NEPHROTIC DYSLIPIDEMIA; NEPHROTIC SYNDROME; NONHUMAN; PROTEIN EXPRESSION; RNA EDITING;

ADENOVIRIDAE; APOLIPOPROTEINS B; CYTIDINE DEAMINASE; DYSLIPIDEMIAS; GENETIC VECTORS; HUMANS; KIDNEY DISEASES; LIVER; RNA EDITING; RNA-BINDING PROTEINS;

ANIMALIA; MAMMALIA;

EID: 77958458658     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.07.030     Document Type: Article

References (34)

1. Hu P., Lu L., Hu B., Du P.F. Characteristics of lipid metabolism under different urinary protein excretion in children with primary nephrotic syndrome. Scand J Clin Lab Invest 2009, 69(6):680-686.
2. Dixit V.M., Hettiaratchi E.S. The mechanism of hyperlipidemia in the nephrotic syndrome. Med Hypotheses 1979, 5(12):1327-1331.
3. Vega G.L., Toto R.D., Grundy S.M. Metabolism of low density lipoproteins in nephrotic dyslipidemia: comparison of hypercholesterolemia alone and combined hyperlipidemia. Kidney Int 1995, 47(2):579-586.
4. Ritz E., Wanner C. Lipid abnormalities and cardiovascular risk in renal disease. J Am Soc Nephrol 2008, 19(6):1065-1070.
5. Dalrymple L.S., Kaysen G.A. The effect of lipoproteins on the development and progression of renal disease. Am J Nephrol 2008, 28(5):723-731.
6. Walker D.B., Walker T.J., Jacobson T.A. Chronic kidney disease and statins: improving cardiovascular outcomes. Curr Atherosclerosis Rep 2009, 11(4):301-308.
7. Kasiske B., Cosio F.G., Beto J., et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004, 4(Suppl. 7):13-53.
8. Anonymous Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II. Arch Intern Med 1993, 153(11):1321-1329.
9. Nassir F., Xie Y., Patterson B.W., Luo J., Davidson N.O. Hepatic secretion of small lipoprotein particles in apobec-1-/- mice is regulated by the LDL receptor. J Lipid Res 2004, 45(9):1649-1659.
10. Dirisamer A., Stadler A., Bucek R.A., Widhalm K. ApoB-100 and ApoB/ApoA-1 ratio in children and adolescents from families with very early myocardial infarction. Acta Paediatr 2006, 95(7):810-813.
11. Lo C.M., Nordskog B.K., Nauli A.M., et al. Why does the gut choose apolipoprotein B48 but not B100 for chylomicron formation?. Am J Physiol Gastrointest Liver Physiol 2008, 294(1):G344-G352.
12. Blanc V., Davidson N.O. C-to-U RNA editing: mechanisms leading to genetic diversity. J Biol Chem 2003, 278(3):1395-1398.
13. Hirano K., Min J., Funahashi T., Baunoch D.A., Davidson N.O. Characterization of the human apobec-1 gene: expression in gastrointestinal tissues determined by alternative splicing with production of a novel truncated peptide. J Lipid Res 1997, 38(5):847-859.
14. Mehta A., Kinter M.T., Sherman N.E., Driscoll D.M. Molecular cloning of apobec-1 complementation factor, a novel RNA-binding protein involved in the editing of apolipoprotein B mRNA. Mol Cell Biol 2000, 20(5):1846-1854.
15. Greeve J., Axelos D., Welker S., Schipper M., Greten H. Distinct promoters induce APOBEC-1 expression in rat liver and intestine. Arterioscler Thromb Vasc Biol 1998, 18(7):1079-1092.
16. Greeve J., Altkemper I., Dieterich J.H., Greten H., Windler E. Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J Lipid Res 1993, 34(8):1367-1383.
17. Davidson N.O., Shelness G.S. Apolipoprotein B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu Rev Nutr 2000, 20:169-193.
18. Hu P., Qin Y.H., Jing C.X., Lei F.Y., Chen P., Li M.F. Association of polymorphisms at restriction enzyme recognition sites of apolipoprotein B and E gene with dyslipidemia in children undergoing primary nephrotic syndrome. Mol Biol Rep 2009, 36(5):1015-1021.
19. Yang Y., Sowden M.P., Smith H.C. Induction of cytidine to uridine editing on cytoplasmic apolipoprotein B mRNA by overexpressing APOBEC-1. J Biol Chem 2000, 275(30):22663-22669.
20. Oka K., Davis A.R., Chan L. Recent advances in liver-directed gene therapy: implications for the treatment of dyslipidemia. Curr Opin Lipidol 2000, 11(2):179-186.
21. Rader D.J., Tietge U.J. Gene therapy for dyslipidemia: clinical prospects. Curr Atherosclerosis Rep 1999, 1(1):58-69.
22. Chen Z., Eggerman T.L., Patterson A.P. Phosphorylation is a regulatory mechanism in apolipoprotein B mRNA editing. Biochem J 2001, 357(Pt 3):661-672.
23. Gerard R.D., Chan L. Adenovirus-mediated gene transfer: strategies and applications in lipoprotein research. Curr Opin Lipidol 1996, 7(2):105-111.
24. Qian X., Balestra M.E., Yamanaka S., Borén J., Lee I., Innerarity T.L. Low expression of the apolipoprotein B mRNA-editing transgene in mice reduces LDL levels but does not cause liver dysplasia or tumors. Arterioscler Thromb Vasc Biol 1998, 18(6):1013-1020.
25. Kozarsky K.F., Bonen D.K., Giannoni F., Funahashi T., Wilson J.M., Davidson N.O. Hepatic expression of the catalytic subunit of the apolipoprotein B mRNA editing enzyme (apobec-1) ameliorates hypercholesterolemia in LDL receptor-deficient rabbits. Hum Gene Ther 1996, 7(8):943-957.
26. Hughes S.D., Rouy D., Navaratnam N., Scott J., Rubin E.M. Gene transfer of cytidine deaminase apoBEC-1 lowers lipoprotein (a) in transgenic mice and induces apolipoprotein B editing in rabbits. Hum Gene Ther 1996, 7(1):39-49.
27. Teng B., Ishida B., Forte T.M., et al. Effective lowering of plasma, LDL, and esterified cholesterol in LDL receptor-knockout mice by adenovirus-mediated gene delivery of ApoB mRNA editing enzyme (Apobec1). Arterioscler Thromb Vasc Biol 1997, 17(5):889-897.
28. Yang Y., Ballatori N., Smith H.C. Apolipoprotein B mRNA editing and the reduction in synthesis and secretion of the atherogenic risk factor, apolipoprotein B100 can be effectively targeted through TAT-mediated protein transduction. Mol Pharmacol 2002, 61(2):269-276.
29. Yamanaka S., Balestra M.E., Ferrell L.D., et al. Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc Natl Acad Sci USA 1995, 92(18):8483-8487.
30. Hersberger M., Patarroyo-White S., Qian X., et al. Regulatable liver expression of the rabbit apolipoprotein B mRNA-editing enzyme catalytic polypeptide 1 (APOBEC-1) in mice lacking endogenous APOBEC-1 leads to aberrant hyperediting. Biochem J 2003, 369(Pt 2):255-262.
31. Yamanaka S., Poksay K.S., Arnold K.S., Innerarity T.L. A novel translational repressor mRNA is edited extensively in livers containing tumors caused by the transgene expression of the apoB mRNA-editing enzyme. Genes Dev 1997, 11(3):321-333.
32. Petit V., Guétard D., Renard M., et al. Murine APOBEC1 is a powerful mutator of retroviral and cellular RNA in vitro and in vivo. J Mol Biol 2009, 385(1):65-78.
33. McClurkin C., Phan S.H., Hsu C.H., et al. Moderate protection of renal function and reduction of fibrosis by colchicine in a model of anti-GBM disease in the rabbit. J Am Soc Nephrol 1990, 1(3):257-265.
34. Greeve J., Jona V.K., Chowdhury N.R., Horwitz M.S., Chowdhury J.R. Hepatic gene transfer of the catalytic subunit of the apolipoprotein B mRNA editing enzyme results in a reduction of plasma LDL levels in normal and watanabe heritable hyperlipidemic rabbits. J Lipid Res 1996, 37(9):2001-2017.